Breast cancer research: where we are and where we should go by Liu, Edison T
Commentary
Breast cancer research: where we are and where we should go
Edison T Liu
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
Received: 19 November 1999
Accepted: 19 November 1999
Published: 14 January 2000
Breast Cancer Res 2000, 2:73–76
© Current Science Ltd
http://breast-cancer-research.com/content/2/2/073
Introduction
Every new year, a common ritual is to reflect on the past
year and resolve to improve, in increments, one’s life for
the next. With the new millennium upon us, the introspec-
tion and the projections take on a grander scale. Certainly,
the span of a thousand years dwarfs the lifetime of any
individual. Therefore, the thoughts and the hopes are for a
community, and not the individual. Furthermore, the millen-
nial resolutions we make are about achieving dreams
beyond the boundaries of current reality. In breast cancer
research, given the progress in the field, it is an appropri-
ate time for us to take stock of our past accomplishments,
and to make projections on where we would like to be.
Then, with these plans in hand, we may plan the first steps
on a journey that will encompass the next 30 generations.
History in brief
We have come a very long way in breast cancer treatment
and care. Our history will tell us, however, that these
advances have only come in the past 30–40 years of a
1000-year retrospective. The first advance in breast
cancer treatment was the work of William Halsted, whose
radical mastectomy provided relief from locally advanced
disease. It is safe to say that very little organized research
was done in breast cancer aetiology or treatment from the
turn of the century to the 1960s. In the 1970s, when clini-
cal trial methodologies were formalized and implemented,
the major clinical advances took place: the equivalence of
the breast sparing surgeries to radical procedures; and
the demonstration that adjuvant chemotherapy can signifi-
cantly alter survival outcome. These treatment advances
also challenged the scientific principle that breast cancer
metastasizes primarily through the lymph nodes, which
dominated the field for over 60 years. In its place, the
primacy of hematogenous spread was acknowledged. The
sole molecular triumph from this period was the develop-
ment of the estrogen receptor as a diagnostic and prog-
nostic factor, as well as the target for chemically based
interventions (diethylstilbestrol and tamoxifen).
From the 1960s to the early 1980s a parallel path of dis-
covery based on molecular biology and cloning provided
the first molecular fundamentals in breast cancer.
Although these findings were important in building an
understanding of the cell biology of experimental systems,
they were of little clinical consequence. The impact
advances in breast cancer research were still from the
clinical sector, and represented significant but incremental
improvements in surgery and adjuvant chemotherapy.
Definitive breast cancer surgery was progressively
reduced in scope, and the introduction of new potent
agents such as doxorubicin and taxol, supportive agents
such as granulocyte colony-stimulating factor, and effec-
tive antiemetics allowed the full application of dose inten-
sity in the adjuvant setting.
In the 1980s and through the 1990s, the advent of poly-
merase chain reaction, advances in molecular cloning, and
transgenic manipulations of the mouse allowed a linkage
between molecular biology and clinical breast cancer
care. For the first time, scientists were able to analyze
microscopic amounts of archival tissues, thus permitting
the association of molecular mutations with clinical
outcome. This was a major advance because breast
lesions were small and getting smaller with better early
detection. It was also during this period that several funda-
mentally important molecular discoveries were made with
impact on clinical breast cancer. First, the discovery that
human epidermal growth factor receptor-2 (HER-2) was
amplified and overexpressed in 20–30% of primary breast
cancers and can induce mammary carcinomas in trans-
genic mice led to its subsequent use as a predictive
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marker of chemotherapeutic selection, and as a target for
an effective antibody-based therapy (Herceptin®; Genen-
tech Inc, San Francisco, California, USA). Second, the
identification of BRCA1 and shortly thereafter of BRCA2
as the major cancer susceptibility genes in human breast
cancers was of practical and conceptual importance.
Practically, a test was derived that can determine predilec-
tion to breast and ovarian cancers. Conceptually, that both
susceptibility genes appear to be primarily involved in
DNA repair suggested that breast cancers emerge from
faulty DNA repair rather than from direct imbalances
between growth and death.
In the 1990s, the promise of impact from early detection
and prevention appeared to be finally validated. Irrefutable
evidence of the effectiveness of mammographic screening
in postmenopausal women made mammography a stan-
dard public health intervention. The Tamoxifen Prevention
Trial, showing a substantial reduction in breast cancer
incidence in those taking tamoxifen, provided proof of the
principle that chemical interventions can significantly alter
the onset of this disease [1].
It is our current belief that the reduction in breast cancer
mortality seen in the USA in the 1990s is due to many of
these clinical and basic discoveries and their effective
implementation – mainly the effects of mammography and
adjuvant therapy. Because the period required for a scien-
tific discovery in cancer research to show an impact in
population statistics is in the range 20–30 years, we are
just now reaping the benefits of work that was begun over
a quarter of a century ago. This, therefore, gives us great
hope that the next quarter of a century will bring tangible
relief to the suffering of women and men with this disease.
With this optimism, the question is, given all the leads that
we have, where should we go?
Where do we go: scientifically?
Rising to this challenge, the US National Cancer Institute
(NCI) in 1997 constituted Progress Review Groups
(PRG) to review the national portfolio of research for par-
ticular disease sites. The ultimate goal was to take heed of
where we are, and to project, for the NCI, where we need
to be. The group studying breast cancer chaired by Drs
Hal Moses (Vanderbilt University, Nashville, Tennessee,
USA) and Nancy Davidson (Johns Hopkins University, Bal-
timore, Maryland, USA) was composed of experts span-
ning a broad range of disciplines and funding
organizations who met eight times from May 1997 to June
1998. Their final report, which can be accessed at the
NCI web site at http://wwwosp.nci.nih.gov/planning/prg/,
provides concise recommendations for improving discov-
ery in all sectors: clinical, epidemiologic, and basic. Struc-
turally, they pointed to the need for programs that foster
deep cross-disciplinary interactions, such as the Special-
ized Programs of Research Excellence; for stronger ties
between academia, government, and industry; for pro-
grams that foster innovation; and for more national reposi-
tories of common reagents such as tumor tissues, clones,
mouse models, and even data. Specifically, the Breast
Cancer PRGs identified 13 critical factors and objectives
that needed attention and that span the continuum of
breast cancer research:
• our limited understanding of biology and developmen-
tal genetics of the normal mammary gland is a barrier
to progress;
• better model systems for human premalignant breast
disease and breast cancer are needed – animal
models, human mammary cell and organ culture;
• our current knowledge of the genetics and biology of
precancerous lesions and their progression to invasive,
metastatic cancers is incomplete (ie gene mutations
and gene expression in breast epithelial cells through
all stages of breast cancer development and progres-
sion);
• key biomarkers and surrogate end points for epidemio-
logic studies and prevention and therapy trials need to
be identified;
• pivotal research needs, appropriate tools and tech-
nologies, and funding is seriously deficient for develop-
ing and disseminating new technologies;
• academic health centers need resources for drug
screening, genomics, and chemistry infrastructure to
support discovery and development of new therapeu-
tics in prevention and treatment – partnerships
between academia, industry and government will be
critical for new drug development efforts;
• faster mechanisms for designing and conducting inno-
vative clinical and translational trials in prevention and
therapy are needed;
• breast cancer research should address patient and
survivor needs;
• the study of behavioral mechanisms in decision-making
that is relevant to breast cancer prevention, detection,
and treatment need more emphasis – the goal is to
support behaviors that are consonant with better
medical outcomes;
• there is a need to attract new investigators to breast
cancer research and to provide multidisciplinary training;
• the multidisciplinary nature of breast cancer research
requires better communications among investigators;
• funding mechanisms should be developed that support
innovation and to accommodate longitudinal studies;
and
• current approaches to informed consent and confiden-
tiality are a major barrier to breast cancer research.
More broadly put, these critical areas for breast cancer
research can be organized into three major clinical opera-
tional goals that we should carry into the next millennium.
The first is to prevent breast cancer from ever occurring;
the second is to cure or control metastatic disease; andhttp://breast-cancer-research.com/content/2/2/073
the third is to develop ways to enhance the lives of those
who have survived breast cancer. Our first line of defense
is good early detection and prevention, but once a cancer
evades this defensive perimeter the cause of mortality
remains metastatic disease. Thus, the achievement of the
first two goals will make a tangible impact on the reduc-
tion in breast cancer incidence and mortality. Success in
the third goal will improve the quality of life of breast
cancer survivors, who represent an ever-increasing
number of women. Unfortunately, it is clear that, despite
our advances, we remain ignorant of many fundamentals.
In prevention, the knowledge deficits that impede our pre-
vention goals are not subtle. That carcinoma in situ of the
breast has similar molecular mutations as those seen in
more advanced cancers suggests that carcinoma in situ is
already an established cancer, and that the true precursor
lesion still needs to be identified. We cannot image pre-
cursor lesions, and thus we have no true measure of end
organ risk assessment. We know very little about how
normal epithelial cells convert to committed cancer cells,
and therefore very little about how to intervene. It is not
even clear that we have reasonable animal models for
breast cancer induction.
In the realm of treatment, we are not certain that the
screens we use to identify good anticancer agents are truly
effective. Although we are beginning to identify molecular
targets for therapeutics that are specific or appropriate for
breast cancer, we do not have good mechanisms to speed
the clinical interrogation of these targeted therapeutics, or
to monitor their success. We are also not taking advantage
of advances in other disciplines such as chemistry and
computer sciences that can speed our rate of discovery.
For those who appear cured of their breast cancer, we are
just beginning to understand the medical sequelae of cyto-
toxic drug exposure, the psychological impact of having
cancer, and possible post-therapy interventions that may
minimize recurrence, and maximize quality of life.
In response to the Breast Cancer PRG report and these
realities of our current knowledge, the NCI developed an
implementation plan that led to a series of initiatives. Inter-
estingly, many of the Breast Cancer PRG recommendations
were similar to those raised by other disease site PRGs and
by review groups examining other aspects of the institute,
such as the developmental therapeutics program, the coop-
erative groups, and the cancer prevention program. This
permitted the NCI to create a number cross-cutting initia-
tives that would address multiple, but overlapping needs,
and that will support disease-based communities who use
the same experimental tools and who face the same logisti-
cal problems. In fact, it was clear to the NCI staff creating
these programs and to our extramural advisors that limiting
these initiatives to only one disease site would create intel-
lectual silos and would not be optimal.
Thus, the Specialized Programs of Research Excellence
have been expanded and better coordinated as an experi-
mental consortium. The cooperative group structure has
been changed to permit more open interaction with individu-
als outside the cooperative group ranks. Pilot studies are
planned within the cooperative group structure that will test
new systems in clinical trials management, such as the
establishment of Clinical Trials Support Units that serve as a
single station to allow access to NCI-supported clinical trials.
The drug discovery program has been dramatically altered,
as manifest in the Rapid Access to Intervention Development
(RAID) program (http://dtp.nci.nih.gov/docs/raid982.html).
RAID was developed to overcome the logistical hurdles of
moving therapeutic agents from academic institutions to the
first clinical studies. New models of review are being
explored that will speed the funding of innovative clinical
trials, and to improve the funding for clinical investigations.
Moreover, innovative approaches for screening new com-
pounds are being supported by such programs as the Non-
Mammalian Organisms for Anti-Cancer Drug Discovery
program (http://www.nih.gov/grants/guide/pa-files/PAR-99-
019.html).
In addressing the problem of animal models, the NCI
created the Mouse Models for Human Cancers Consor-
tium, which includes 19 of the nation’s best groups for the
purpose of supporting data sharing, the development of
new models, and other issues raised by the PRG. In bring-
ing new technologies to the field, the Director’s Challenge
grant will fund institutions to use novel technologies in
devising molecular classifications for human cancers
including breast. A recent competitive supplement sup-
ported over 20 cancer centers to develop their indigenous
microarray programs. Phased Innovation Awards were
made available whereby investigators could receive ‘seed’
resources to explore new leads without much preliminary
data, that can be followed by larger phase II funds if the
exploration was successful.
The Early Detection Research Network is funding a
number of sites to identify early markers of cancer, includ-
ing breast, and to support their development for clinical
use (http://www.nih.gov/grants/guide/rfa-files/RFA-CA-
98-028.html). The NCI has recently funded the Diagnostic
Imaging Network which is a multi-institutional network for
cooperative studies in diagnostic imaging, including innov-
ative breast imaging technologies (http://www.acrin.org).
Acknowledging the importance of genetics in epidemio-
logic investigations of breast cancer, the NCI has estab-
lished a Cancer Genetics Network that is a multicenter
consortium for the study of genetic susceptibility
(http://www.nih.gov/news/pr/july98/nci-28.htm). Plans are
being developed for funded coordination of large cohort
studies, especially in the realm of biomarker analysis, and
support for cancer communications research is undergo-
ing rapid expansion. A detailed summary of these NCI ini-tiatives in breast cancer research can be viewed at the
NCI website: http://www.nci.nih.gov/bci.html.
Where do we go: socially?
It would be incorrect to highlight the scientific advances
without acknowledging impact of the social climate on
science. What was permissive to the development of
oncology and clinical investigations in oncology in the
latter half of the 1900s was the willingness of individuals
to talk about their cancer, and the reversal of the nihilistic
view of cancer treatment that pervaded clinical practice.
What has uniquely characterized the 1990s, however, has
been the beginnings of an unprecedented cooperation
between clinical, population, and basic scientists in attack-
ing breast cancer. Although some of this is due to the
power of the technologies that permit basic questions in
human diseases to be asked, and to new funding mecha-
nisms such as the Specialized Programs of Research
Excellence, a lion share of the credit must be given to the
force of the breast cancer advocacy movement. Not only
were they able to increase funding for breast cancer
research, but they also participated substantially in forcing
disparate scientific communities and funding agencies to
work together. This new spirit of collaboration, along with
the scientific tools that are now available, has fueled an
unparalleled rate of scientific discovery in breast cancer
research.
We will need to extend this sense of collaboration and
linkage from the academic realm to a wider context. For
example interactions between advocacy groups, industry,
academia, and government will be needed to tackle diffi-
cult clinical and research resource questions. Data
sharing, common data elements, and the posting of
primary data will be progressively more important in less-
ening redundancy and in accelerating the principles of evi-
dence-based medicine. Clinical investigations cannot
proceed without proper support from public or private
health insurance organizations, and therefore a funding
pact between insurance industry, government, and
research organizations for clinical research will soon be
necessary. There is no question that effective communica-
tions and organization among funding health agencies will
accelerate the implementation of effective prevention,
screening, and treatment approaches. This, by itself, will
significantly reduce the time from discovery to clinical
impact. Finally, legal resolutions to the current problems
that involve informed consent and confidentiality will be
needed to advance clinical and epidemiologic investiga-
tions. This will require consensus among professional,
legal, ethics, and government bodies.
Conclusion
The foundations for a robust and innovative national port-
folio of discovery and implementation have now been
established. Now it is in the hands of capable investiga-
tors to take advantage of these platforms and resources to
make an impact. Given how far we have gone in the latter
40 of the past 1000 years, it is clearly within our grasp to
achieve the millennial goals noted herein: to prevent
breast cancer from ever starting, to cure metastatic
disease, and to make the lives of those who have survived
breast cancer better.
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